South Africa wants to sell or swap its first batch of the AstraZeneca COVID-19 vaccine just days after getting it — because a new study suggested it might not protect against its dominant mutation.
South Africa wants to sell or swap its first batch of the AstraZeneca COVID-19 vaccine just days after getting it — because a new study suggested it might not protect against its dominant mutation.
